CR6501A - Modulacion de la funcion del tejido excitable por medio de eritropoietina administrada perifericamente - Google Patents

Modulacion de la funcion del tejido excitable por medio de eritropoietina administrada perifericamente

Info

Publication number
CR6501A
CR6501A CR6501A CR6501A CR6501A CR 6501 A CR6501 A CR 6501A CR 6501 A CR6501 A CR 6501A CR 6501 A CR6501 A CR 6501A CR 6501 A CR6501 A CR 6501A
Authority
CR
Costa Rica
Prior art keywords
erythropoietin
peripherically
administrated
modulation
tissue function
Prior art date
Application number
CR6501A
Other languages
English (en)
Spanish (es)
Inventor
Brines Michael
Original Assignee
Kenneth S Warren Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth S Warren Lab filed Critical Kenneth S Warren Lab
Publication of CR6501A publication Critical patent/CR6501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CR6501A 1999-04-13 2001-11-13 Modulacion de la funcion del tejido excitable por medio de eritropoietina administrada perifericamente CR6501A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29093899A 1999-04-13 1999-04-13
US54722000A 2000-04-11 2000-04-11

Publications (1)

Publication Number Publication Date
CR6501A true CR6501A (es) 2004-04-15

Family

ID=26966493

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6501A CR6501A (es) 1999-04-13 2001-11-13 Modulacion de la funcion del tejido excitable por medio de eritropoietina administrada perifericamente

Country Status (21)

Country Link
EP (1) EP1171147A4 (is)
JP (1) JP2003520194A (is)
KR (2) KR101012932B1 (is)
CN (1) CN1607957B (is)
AU (1) AU784550B2 (is)
BG (1) BG65353B1 (is)
BR (1) BR0009737A (is)
CA (1) CA2383940A1 (is)
CR (1) CR6501A (is)
CZ (1) CZ20013695A3 (is)
EA (1) EA004766B1 (is)
HU (1) HUP0201598A3 (is)
IL (2) IL145895A0 (is)
IS (1) IS6104A (is)
MX (1) MXPA01010177A (is)
NO (1) NO20014991L (is)
NZ (4) NZ560696A (is)
PL (1) PL352223A1 (is)
SK (1) SK14412001A3 (is)
TR (2) TR200103785T2 (is)
WO (1) WO2000061164A1 (is)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
ATE444077T1 (de) 2000-06-30 2009-10-15 Tokyo Metropolitan Inst Of Ger Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
DE60219961T8 (de) * 2001-02-02 2008-04-17 Ortho-Mcneil Pharmaceutical, Inc. Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
ATE542904T1 (de) 2001-10-29 2012-02-15 Crucell Holland Bv Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
PT1465987E (pt) 2001-12-07 2008-04-15 Crucell Holland Bv Produção de vírus, isolados virais e vacinas
CN1612747A (zh) 2002-01-09 2005-05-04 克鲁塞尔荷兰公司 促红细胞生成素在预防或治疗心力衰竭中的用途
AU2002307635A1 (en) * 2002-04-19 2003-11-03 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
EP1552298A4 (en) * 2002-07-01 2006-11-08 Kenneth S Warren Inst Inc RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
EP1633383A4 (en) * 2003-03-27 2008-05-21 Janssen Pharmaceutica Nv USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
WO2004099396A1 (en) 2003-05-09 2004-11-18 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
GB0525540D0 (en) * 2005-12-15 2006-01-25 Isis Innovation New treatment
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
CN101062407A (zh) * 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
US8133860B2 (en) * 2006-07-20 2012-03-13 Rosalind Franklin University Of Medicine And Science Facilitation of resuscitation from cardiac arrest by erythropoietin
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
KR20200075044A (ko) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
RU2385746C1 (ru) * 2008-07-18 2010-04-10 Владимир Алексеевич Шатров Способ лечения детского церебрального паралича
RU2432899C1 (ru) * 2010-03-23 2011-11-10 Владимир Алексеевич Тупиков Способ прогнозирования рецидива эквинусной и эквиноварусной деформаций стопы после их раннего хирургического лечения у детей с дцп
RU2519695C2 (ru) * 2010-07-21 2014-06-20 Олег Ильич Эпштейн Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen

Also Published As

Publication number Publication date
EA004766B1 (ru) 2004-08-26
WO2000061164A1 (en) 2000-10-19
TR200103785T2 (tr) 2002-06-21
CN1607957A (zh) 2005-04-20
KR101012932B1 (ko) 2011-02-08
CZ20013695A3 (cs) 2002-02-13
HUP0201598A2 (en) 2002-09-28
JP2003520194A (ja) 2003-07-02
HUP0201598A3 (en) 2002-10-28
AU4348700A (en) 2000-11-14
KR20020000874A (ko) 2002-01-05
PL352223A1 (en) 2003-08-11
NZ533098A (en) 2006-04-28
EA200101073A1 (ru) 2002-10-31
CN1607957B (zh) 2012-10-10
SK14412001A3 (sk) 2002-03-05
TR200402194T2 (tr) 2004-10-21
IL145895A0 (en) 2002-07-25
CA2383940A1 (en) 2000-10-19
NZ560696A (en) 2010-03-26
IL145895A (en) 2010-05-31
KR100883232B1 (ko) 2009-02-10
MXPA01010177A (es) 2004-09-10
IS6104A (is) 2001-10-11
EP1171147A4 (en) 2003-05-14
NZ545478A (en) 2008-04-30
NO20014991L (no) 2001-11-15
AU784550B2 (en) 2006-05-04
BG65353B1 (bg) 2008-03-31
KR20070094997A (ko) 2007-09-27
NO20014991D0 (no) 2001-10-12
BR0009737A (pt) 2003-01-14
NZ514690A (en) 2004-07-30
EP1171147A1 (en) 2002-01-16
BG106058A (en) 2002-12-29

Similar Documents

Publication Publication Date Title
CR6501A (es) Modulacion de la funcion del tejido excitable por medio de eritropoietina administrada perifericamente
FI964323A0 (fi) Kirurginen implantaatti, väline tai sen osa
DE60016670D1 (de) Kosmetisches Mittel enthaltend mindestens einen Hydroxystilben und Ascorbinsäure
CL2004000675A1 (es) Uso de una combinacion de androgeno de origen biogenico o sintetico y un estrogeno de origen biogenico o sintetico para preparar un medicamento util en el tratamiento del hipogonadismo y enfermedades hipofisis o glandula pituitaria en hombres, para e
ES2192301T3 (es) Derivados de resorcinol.
ATE336255T1 (de) Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben
DE60107711D1 (de) Steuerbare schlaufenstrukturen zur unterstützung von diagnostischen und therapeutischen elementen in kontakt mit körpergewebe
CL2004000674A1 (es) Sistema terapeutico transdermico que comprende al menos una sustancia activa farmaceutica, al menos un disruptor de la estructura y/o al menos un formador de estructura en una matriz comun.
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
YU83600A (sh) Adenozin a3 receptorski modulatori
ATE267613T1 (de) Arzneimittel und deren verwendung
PT1196444E (pt) Conjugados de exendina-4 e seus usos medicos
BR0210631A (pt) Composição farmacêutica de liberação prolongada
DE59407457D1 (de) Blockierung der anlagerung von keimen an menschliche zellen
PL353738A1 (en) Composition containing an active substance, production and use thereof
AR017406A1 (es) Articulo absorbente descartable que tiene un miembro para el manejo de la materia fecal
BR0206852A (pt) Conjugados de polìmero de neublastina e métodos para uso dos mesmos
SV2002000062A (es) Derivados monofluoroalquilo ref. x-12964
DE60020414D1 (de) Lichtmodulationsvorrichtung, Ansteurungsverfahren davon, und flache Anzeigetafel
ES2185317T3 (es) Material soporte para usos medicos.
AR022050A1 (es) Composiciones de tenido por oxidacion de las fibras queratinicas y procedimiento de tenido que utiliza esta composicion
AU5157596A (en) Biodegradable device
ATE353642T1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
ES2160044A1 (es) Oxidacion de *-pineno.
BR0002772A (pt) Uso de ligantes melatoninérgicos na obtenção de composições farmacêuticas pretendidas para a prevenção ou o tratamento de patologias do sistema gastrintestinal

Legal Events

Date Code Title Description
FC Refusal